Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-Cullin 5-RING E3 ubiquitin ligase

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3320-3328

  Han, Xue ^a,c,d   Liang, Weizi ^a   Hua, Deping ^a   Zhou, Xiaohong ^b,c   Du, Juan ^b   Evans, Sean L ^c   Gao, Qimeng ^c   Wang, Hong ^b   Viqueira, Rachel ^e   Wei, Wei ^a,c   Zhang, Wenyan ^b   Yu, Xiao Fang ^a,c,d  

^a TIANJIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d SynBio Research Platform   (China)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; CULLIN 5; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; GENETIC CONSERVATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CORE BINDING FACTOR BETA SUBUNIT; CULLIN PROTEINS; EVOLUTION, MOLECULAR; GENE PRODUCTS, VIF; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE ALIGNMENT; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84894600842     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03833-13     Document Type: Article

References (51)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
2. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31. http://dx.doi.org/10.1016/S0092-8674(03)00515-4.
3. Bieniasz PD. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109-1115. http://dx.doi.org/10.1038/ni1125.
4. Chiu YL, Greene WC. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090350.
5. Cullen BR. 2006. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80:1067-1076. http://dx.doi.org/10.1128/JVI.80.3.1067-1076.2006.
6. Goff SP. 2004. Retrovirus restriction factors. Mol. Cell 16:849-859. http://dx.doi.org/10.1016/j.molcel.2004.12.001.
7. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877. http://dx.doi.org/10.1038/nri1489.
8. Malim MH, Emerman M. 2008. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398. http://dx.doi.org/10.1016/j.chom.2008.04.008.
9. Navarro F, Landau NR. 2004. Recent insights into HIV-1 Vif. Curr. Opin. Immunol. 16:477-482. http://dx.doi.org/10.1016/j.coi.2004.05.006.
10. Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV. 2005. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases predicted by computational analysis. Cell Cycle 4:1281-1285. http://dx.doi.org/10.4161/cc.4.9.1994.
11. Rose KM, Marin M, Kozak SL, Kabat D. 2004. The viral infectivity factor (Vif) of HIV-1 unveiled. Trends Mol. Med. 10:291-297. http://dx.doi.org/10.1016/j.molmed.2004.04.008.
12. Rose KM, Marin M, Kozak SL, Kabat D. 2004. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279:41744-41749. http://dx.doi.org/10.1074/jbc.M406760200.
13. Turelli P, Trono D. 2005. Editing at the crossroad of innate and adaptive immunity. Science 307:1061-1065. http://dx.doi.org/10.1126/science.1105964.
14. Niewiadomska AM, Yu XF. 2009. Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr. Top. Microbiol. Immunol. 339:1-25. http://dx.doi.org/10.1007/978-3-642-02175-6_1.
15. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
16. Liu B, Yu X, Luo K, Yu Y, Yu XF. 2004. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2072-2081. http://dx.doi.org/10.1128/JVI.78.4.2072-2081.2004.
17. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
18. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798. http://dx.doi.org/10.1074/jbc.M313093200.
19. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
20. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
21. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089 591.
22. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866. http://dx.doi.org/10.1101/gad.1249904.
23. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872. http://dx.doi.org/10.1101/gad.1250204.
24. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A. 102:11444-11449. http://dx.doi.org/10.1073/pnas.0502440102.
25. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259-17265. http://dx.doi.org/10.1074/jbc.M602413200.
26. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. 2007. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21:217-222. http://dx.doi.org/10.1096/fj.06-6773com.
27. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550. http://dx.doi.org/10.1016/j.jmb.2007.07.029.
28. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299. http://dx.doi.org/10.1016/j.virol.2006.02.002.
29. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
30. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D. 2007. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81:13235-13241. http://dx.doi.org/10.1128/JVI.00204-07.
31. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374-2381. http://dx.doi.org/10.1128/JVI.01898-08.
32. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
33. Schrofelbauer B, Senger T, Manning G, Landau NR. 2006. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80: 5984-5991. http://dx.doi.org/10.1128/JVI.00388-06.
34. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. http://dx.doi.org/10.1371/journal.ppat.0010006.
35. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115. http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006.
36. Chen G, He Z, Wang T, Xu R, Yu XF. 2009. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83:8674-8682. http://dx.doi.org/10.1128/JVI.00653-09.
37. Dang Y, Wang X, Zhou T, York IA, Zheng YH. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552. http://dx.doi.org/10.1128/JVI.00651-09.
38. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. 2013. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J. Virol. 87: 1906-1911. http://dx.doi.org/10.1128/JVI.02199-12.
39. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. 2012. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J. Virol. 86:2874-2877. http://dx.doi.org/10.1128/JVI.06950-11.
40. Hultquist JF, McDougle RM, Anderson BD, Harris RS. 2012. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 28:1543-1551. http://dx.doi.org/10.1089/aid.2012.0142.
41. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
42. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. 2013. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49:632-644. http://dx.doi.org/10.1016/j.molcel.2012.12.012.
43. Salter JD, Lippa GM, Belashov IA, Wedekind JE. 2012. Core-binding factor beta increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 51:8702-8704. http://dx.doi.org/10.1021/bi301244z.
44. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
45. Zhou X, Evans SL, Han X, Liu Y, Yu XF. 2012. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PLoS One 7:e33495. http://dx.doi.org/10.1371/journal.pone.0033495.
46. de Bruijn MF, Speck NA. 2004. Core-binding factors in hematopoiesis and immune function. Oncogene 23:4238-4248. http://dx.doi.org/10.1038/sj.onc.1207763.
47. Ito Y. 2008. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 99:33-76. http://dx.doi.org/10.1016/S0065-230X(07)99002-8.
48. Dettenhofer M, Yu XF. 1999. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73:1460-1467.
49. Yu XF, Dawson L, Tian CJ, Flexner C, Dettenhofer M. 1998. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J. Virol. 72:3412-3417.
50. Zhou X, Han X, Zhao K, Du J, Evans SL, Wang H, Li P, Zheng W, Rui Y, Kang J, Yu XF. 18 December 2013. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression. J. Virol. http://dx.doi.org/10.1128/JVI.03604-13.
51. 2 arrest. Cell. Microbiol. 14:1745-1756. http://dx.doi.org/10.1111/j.1462-5822.2012.01835.x.